Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 18/20 | 0.59 |
| ▸ | PPARA | Q07869 | 16/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21057201 | 1.00 | LDHA (0.59) | LDHAPPARGPPARA | |
| SCHEMBL21057203 | 1.00 | LDHA (0.59) | LDHAPPARGPPARA | |
| SCHEMBL21057169 | 0.88 | LDHA (0.58) | LDHAPPARGPPARA | |
| SCHEMBL21057172 | 0.88 | LDHA (0.58) | LDHAPPARGPPARA | |
| SCHEMBL30575130 | 0.86 | PPARG (0.49) | LDHAPPARGPPARA | |
| SCHEMBL30575133 | 0.85 | PPARG (0.44) | LDHAPPARGPPARA | |
| SCHEMBL30575129 | 0.85 | PPARG (0.44) | LDHAPPARGPPARA | |
| SCHEMBL21057232 | 0.84 | LDHA (0.61) | LDHAPPARGPPARA | |
| SCHEMBL21057234 | 0.84 | LDHA (0.61) | LDHAPPARGPPARA | |
| SCHEMBL4187184 | 0.84 | LDHA (0.61) | LDHAPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | claimed |
| EP-3723745-B1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-06-19 | — | — | EP | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | LDHA 2645/4885PPARG 3332/4885PPARA 3247/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | LDHA 2645/4885PPARG 3332/4885PPARA 3247/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | LDHA 2645/4885PPARG 3332/4885PPARA 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.